GSA Capital Partners’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $790K | Buy |
45,252
+17,800
| +65% | +$311K | 0.06% | 617 |
|
|
2025
Q1 | $345K | Buy |
27,452
+9,878
| +56% | +$124K | 0.03% | 1047 |
|
|
2024
Q4 | $185K | Sell |
17,574
-81,326
| -82% | -$856K | 0.01% | 1432 |
|
|
2024
Q3 | $1.43M | Buy |
98,900
+39,921
| +68% | +$579K | 0.11% | 249 |
|
|
2024
Q2 | $502K | Sell |
58,979
-69,910
| -54% | -$595K | 0.04% | 963 |
|
|
2024
Q1 | $1.32M | Buy |
128,889
+13,545
| +12% | +$138K | 0.1% | 277 |
|
|
2023
Q4 | $632K | Buy |
+115,344
| New | +$632K | 0.05% | 639 |
|
|
2023
Q2 | – | Sell |
-10,744
| Closed | -$70K | – | 1918 |
|
|
2023
Q1 | $70K | Buy |
+10,744
| New | +$70K | 0.01% | 1385 |
|
|
2022
Q2 | – | Sell |
-22,894
| Closed | -$80K | – | 1773 |
|
|
2022
Q1 | $80K | Buy |
22,894
+11,303
| +98% | +$39.5K | 0.01% | 1316 |
|
|
2021
Q4 | $77K | Buy |
+11,591
| New | +$77K | 0.01% | 1331 |
|